Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORMINEST FE vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (FSH, LH). Increases cervical mucus viscosity, reducing sperm penetration. Norethindrone acetate is metabolized to norethindrone, which binds to progesterone receptors; ethinyl estradiol binds to estrogen receptors, providing contraceptive effect and cycle control.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy (FDA-approved),Oral contraceptive for women with iron deficiency (due to ferrous fumarate component)
Prevention of pregnancy
1 tablet orally once daily, starting on day 1 of menstrual cycle; each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (21 active tablets) followed by 7 ferrous fumarate tablets.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours. Clinical context: steady-state in 5-7 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Norethindrone acetate: extensively metabolized in the liver via reduction and conjugation. Active metabolite: norethindrone. Ethinyl estradiol: metabolized via CYP3A4 and conjugation (glucuronidation and sulfation). Undergoes enterohepatic recirculation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal 60-80% as metabolites, fecal 20-30% via bile, unchanged drug <5%.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: 61% bound to albumin, 36% to SHBG; ethinyl estradiol: 98% bound to albumin.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: 3.6 ± 0.7 L/kg; ethinyl estradiol: 1.8 ± 0.5 L/kg. Reflects distribution to tissues.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Norethindrone: 64% (oral); ethinyl estradiol: 48% (oral) due to first-pass metabolism.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate impairment; contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in Child-Pugh class B or C; use with caution in Child-Pugh class A; monitor liver function.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated for use before menarche; for adolescents, same dosing as adults after menarche; safety and efficacy established in females of reproductive age.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in postmenopausal women; no dosing studies in geriatric population; use not recommended.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders: venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction.,Cigarette smoking increases cardiovascular risk; advise not to smoke.,Elevated blood pressure: monitor regularly.,Gallbladder disease: increased risk of cholelithiasis.,Liver tumors: benign and malignant hepatic adenomas reported.,Carbohydrate and lipid metabolism: monitor in diabetics and those with dyslipidemia.,Headache: may worsen or initiate migraine; discontinue if new headache pattern or persistent.,Bleeding irregularities: breakthrough bleeding and spotting are common; evaluate if persistent.,Ocular effects: retinal thrombosis may cause partial or complete loss of vision; discontinue if proptosis, diplopia, or papilledema.,Depression: discontinue if severe or persistent.,Iron overload: contraindicated in patients with hemosiderosis or hemochromatosis (due to ferrous fumarate).
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes/day) in women over 35,Hemosiderosis or hemochromatosis (due to ferrous fumarate)
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No significant food interactions with the hormonal components. Iron tablets may cause gastrointestinal upset; taking with food may reduce nausea but can decrease iron absorption. Avoid high-calcium foods with iron pills. Grapefruit juice may increase estrogen levels; limit intake.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
NORMINEST FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent exposure in large epidemiologic studies, but increased risk of cardiovascular and limb anomalies reported with higher doses. Second/third trimester: Androgenic effects causing clitoromegaly, labial fusion, and potential for impaired fetal growth. Postnatal: Possible long-term neurodevelopmental effects.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
NORMINEST FE reduces milk production and quality. Estrogen and progestin are excreted in breast milk. M/P ratio unreported. Use only if benefit outweighs risk; poorest choice for lactation suppression due to thromboembolic risks.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated during pregnancy; no dose adjustment applicable. If inadvertent exposure, discontinue immediately. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) do not apply as drug is not used during pregnancy.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Norminest FE is a combination oral contraceptive containing norethindrone and ethinyl estradiol with ferrous fumarate (iron) in the placebo pills. The iron component does not provide contraception. Breakthrough bleeding is more common with low-dose formulations. Patients should be counseled that the iron pills are not active hormonal pills. Monitor for signs of thromboembolism, especially in smokers over 35 years old.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill daily at the same time each day. Do not skip doses.,The last row of pills (typically brown) are iron tablets and do not provide contraception.,Use a backup method (e.g., condoms) if you miss two or more active pills.,Common side effects include nausea, breast tenderness, and spotting between periods.,Seek immediate medical attention for leg pain, shortness of breath, or severe headache.,Smoking increases risk of serious cardiovascular side effects, especially if you are over 35.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORMINEST FE vs ALYACEN 1/35, answered by our medical review team.
NORMINEST FE is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (FSH, LH). Increases cervical mucus viscosity, reducing sperm penetration. Norethindrone acetate is metabolized to norethindrone, which binds to progesterone receptors; ethinyl estradiol binds to estrogen receptors, providing contraceptive effect and cycle control.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORMINEST FE and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORMINEST FE is: 1 tablet orally once daily, starting on day 1 of menstrual cycle; each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (21 active tablets) followed by 7 ferrous fumarate tablets.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORMINEST FE and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORMINEST FE is classified as Category C. NORMINEST FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from inadvertent exposure in large epidemi. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.